Cancer Biopsies - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

The Cancer Biopsies Market size is estimated at USD 29.93 billion in 2024, and is expected to reach USD 51.48 billion by 2029, growing at a CAGR of 11.46% during the forecast period (2024-2029).

The emergence of COVID-19 had a significant impact on the cancer biopsies market. During the initial phase of the pandemic, due to social distancing measures, hospital visits were drastically reduced, and only patients with emergencies were allowed. Thus, there was a decrease in cancer biopsies in 2020, which adversely impacted the market's growth. However, the adoption of new technologies increased post the pandemic, creating created new opportunities for the studied market.Liquid biopsies gained demand for detecting genetic alterations in cancer patients during the later phases of the pandemic. As per an article published in the PMC Journal in September 2021, the researchers recommended performing liquid biopsies, which represented a valid and less time-consuming diagnostic approach for managing lung cancer patients during the COVID-19 period than conventional tissue and cytological specimens. Hence, there was high demand for advanced technologies, which fueled the market's growth.

Factors such as the rising burden of oncology diseases, increasing adoption of liquid biopsies, advancement in technologies, and rising awareness of inherited oncology disorders and genetic testing are expected to contribute to the growth of the studied market.

The rise in cancer cases is also playing a key role in the cancer biopsies market's growth. According to CanRehab-2022, new cancer cases are expected to grow to 27.5 million by 2040, globally. According to the National Cancer Institute (NCI) 2022 update, there were around 83,730 new bladder cancer cases reported in 2021 in the United States, along with 284,200 breast cancer cases and 149,500 colon and rectal cancer cases. These figures indicate a huge burden of cancer among the population, acting as a potential elevating factor for the cancer biopsies market's growth.

The technological advancements and product launches by key players are also contributing to the growth of the market. For instance, in July 2022, BillionToOne Inc. launched its first oncology liquid biopsy product, Northstar Select and Northstar Response. The products are currently available for research use with selected academic cancer centers.

However, risks associated with biopsy procedures are expected to restrain the market's growth over the forecast period.

Cancer Biopsies Market Trends

Breast Cancer Segment is Expected to Grow During the Forecast Period

The breast cancer segment is expected to witness significant growth over the forecast period, largely attributed to the rising burden of breast cancer.

For instance, according to Breastcancer.org 2022 update, an estimated 287,850 new cases of invasive breast cancer were to be diagnosed in US women in 2022, along with 51,400 new cases of non-invasive (in situ) breast cancer. According to the American Society of Clinical Oncology (ASCO) January 2022 update, there are more than 3.8 million women in the United States with a history of breast cancer, inclduing women currently being treated and those who have completed their treatment.

According to 2021 statistics published by Breast Cancer Now, about 55,000 women are diagnosed with breast cancer in the United Kingdom every year. As per the same source above, 46,000 people are diagnosed with breast cancer in England every year, followed by 4,700 in Scotland, 2,800 in Wales, and 1,500 in Northern Ireland. Thus, the high burden of breast cancer cases across the world is expected to increase the diagnosis and biopsies testing, thus accelerating the segment's growth over the forecast period.

According to the January 2022 update of the American Cancer Society (ACS), the application of biopsies for breast cancer detection is increasing, and most often, a core-needle biopsy is performed rather than a surgical biopsy. Thus, the increased application of cancer biopsies for breast cancer is fueling the segment's growth.

North America is Anticipated to Witness Growth During the Forecast Period

The North American region held the largest share and is expected to maintain the same over the forecast period. Technological advancements, a high burden of cancer prevalence, and an increase in product approval and launches are major factors attributed to the market's growth.

There is a burden of cancer across the countries in North America. According to the NIH data published in March 2022, HER-2 negative cancer accounted for around 15-20% of the total breast cancer cases across the United States in 2021, and an estimated 287,850 new cases of female breast cancer were to be diagnosed in 2022.

In addition, according to the March 2022 update by the Government of Canada, breast cancer is Canada's second most frequent cancer, and 1 in every 8 women is likely to be diagnosed with breast cancer in the country. Thus, the growing prevalence of cancer across different nations in the region is expected to propel the demand for cancer biopsies, further fueling the market's growth over the forecast period.

Product innovations by major players and research institutes are also contributing to the market's growth. For instance, in June 2022, UCF researchers developed a liquid biopsy technique to help detect metastatic cancer in blood. It could help patients suffering from breast and lung cancers better monitor their disease. Thus, such developments are anticipated to contribute to the market's growth.

Cancer Biopsies Industry Overview

The cancer biopsies market is moderately competitive. In terms of market share, few of the major players currently dominate the market. With the rising patient awareness levels and high prevalence of cancer diseases, many regional players are expected to be a part of the cancer biopsies market over the forecast period. Some of the major players in the market are QIAGEN NV, Illumina Inc., Becton, Dickinson and Company, Myriad Genetics, and Thermo Fisher Scientific.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support